Application of fosfolic acid sodium in preparation of medicines for preventing and treating coronavirus

The invention relates to application of fosfolic acid sodium in preparation of medicines for preventing and treating coronavirus, and particularly discloses application of fosfolic acid sodium or a pharmaceutically acceptable salt, isotope, stereoisomers, a stereoisomer mixture, tautomers, esters, amides or prodrugs thereof in preparation of medicines for preventing and/or treating diseases causedby a coronavirus. The coronavirus is novel coronavirus SARS-Cov-2, SARS-CoV, HCoV 229E, NL63, OC43, HKU1 and MERS-CoV. The median effective concentration of the fosfolic acid sodium to the novel coronavirus of the COVID-19 is 0.89 [mu]M, and the treatment index is 449.43, which indicates that the fosfolic acid sodium has a good treatment window. 本发明涉及膦甲酸钠在制备预防和治疗冠状病毒的药物中的应用，具体公开了。膦甲酸钠或其可药用的盐、同位素、立体异构体、立体异构体的混合物、互变异构体、酯、酰胺或前药在制备预防和/或治疗冠状病毒所致疾病的药物中的应用。所述的冠状病毒为新型冠状病毒SARS-Cov-2、SARS-CoV、HCoV 229E、NL63、OC43、HKU1和MERS-CoV。膦甲酸钠对新冠肺炎新型冠状病毒的半数有效浓度为0.89μM,治疗指数为449.43，表明具有一个良好的治疗窗口。